Disease/Infection News

RSS

Scientists engineer new protein that prevents HIV virus entry into cells

In what could be a potential breakthrough in the battle against AIDS and a major development in the rational design of new drugs, scientists have engineered a new protein that prevents the virus from entering cells.

1 Apr 2011

EPIDEMICS³ International Conference on Infectious Disease Dynamics to take place in Boston, in Nov 2011

Following the inaugural Epidemics¹ Conference in Asilomar, USA in 2008, and the second conference Epidemics² in Athens, Greece in 2009, both highly successful meetings with both more than 230 participants, the organizers are pleased to announce that the Third International Conference on Infectious Disease Dynamics - EPIDEMICS³ - will take place in Boston, USA, in November 2011.

1 Apr 2011

New research finds HIV virus's V3 loop as attractive vaccine target

A section of the AIDS virus's protein envelope once considered an improbable target for a vaccine now appears to be one of the most promising, new research by Dana-Farber Cancer Institute scientists indicates.

1 Apr 2011

U.N. Secretary-General releases report assessing global response to HIV/AIDS

Nearly 30 years since researchers first described HIV/AIDS, U.N. Secretary-General Ban Ki-moon on Thursday in Nairobi, Kenya, released a report assessing the global HIV/AIDS response, Agence France-Presse reports.

1 Apr 2011

Study: Pseudokinases can play a crucial role in pathogen-based disease

Researchers from the University of Pittsburgh and Stanford University discovered that a supposedly inactive protein actually plays a crucial role in the ability of one the world's most prolific pathogens to cause disease, findings that suggest the possible role of similarly errant proteins in other diseases.

1 Apr 2011

Novartis, Intercell to initiate Pseudomonas vaccine trial in ventilated ICU patients

Today Intercell AG announced that it has agreed with Novartis to advance Intercell's investigational Pseudomonas aeruginosa vaccine into a confirmatory clinical efficacy trial in ventilated ICU patients.

1 Apr 2011

Tibotec presents TMC435 phase 2b study interim results against HCV at EASL meeting

Medivir AB, the emerging research-based specialty pharmaceutical company focused on infectious diseases, announces that their partner, Tibotec has presented the results of a planned Week 24 interim analysis of the phase 2b ASPIRE study for TMC435 in treatment experienced hepatitis C patients in a late-breaker session at the 46th Annual meeting of the European Association for the Study of the Liver, Berlin, Germany.

1 Apr 2011

New data confirms antiviral activity of fluvastatin in patients with HCV

New data presented today at the International Liver CongressTM confirm the antiviral activity of fluvastatin -- commonly used as a cholesterol-lowering treatment -- in patients with chronic hepatitis C.

1 Apr 2011

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced results from several new data analyses from the pivotal Phase III studies evaluating the addition of its investigational oral protease inhibitor VICTRELIS to peginterferon alfa-2b and ribavirin in adult patients with chronic hepatitis C virus genotype 1 infection.

1 Apr 2011

DNA damage can lead to regulation of inflammatory responses

Researchers offer the first evidence that DNA damage can lead to the regulation of inflammatory responses, the body's reaction to injury. The proteins involved in the regulation help protect the body from infection.

1 Apr 2011

Study: Electronic faucets more likely to become contaminated with bacteria

Researchers at The Johns Hopkins University School of Medicine have determined that electronic faucets are more likely to become contaminated with unacceptably high levels of bacteria, including Legionella spp., compared with traditional manually operated faucets.

1 Apr 2011

Vertex announces final results from Phase 3 REALIZE study against HCV

Vertex Pharmaceuticals Incorporated today announced final results from its pivotal Phase 3 REALIZE study that evaluated people with genotype 1 chronic hepatitis C whose prior treatment with pegylated-interferon and ribavirin was unsuccessful either because they relapsed, had a partial response or had a null response.

1 Apr 2011

Biota Scientific receives BARDA contract to develop single-dose antiviral drug

A contract has been awarded to develop a long-acting single-dose antiviral drug for use in the United States, the U.S. Biomedical Advanced Research and Development Authority announced today.

1 Apr 2011

Hands-free electronic water faucets more likely to be contaminated with hazardous bacteria

A study of newly installed, hands-free faucets at The Johns Hopkins Hospital, all equipped with the latest electronic-eye sensors to automatically detect hands and dispense preset amounts of water, shows they were more likely to be contaminated with one of the most common and hazardous bacteria in hospitals compared to old-style fixtures with separate handles for hot and cold water.

1 Apr 2011

Conatus CTS-1027 Phase 2 trial results against HCV presented at EASL meeting

Conatus Pharmaceuticals Inc. announced today 24-week interim results from a clinical trial with CTS-1027 in combination with Peginterferon Alpha-2a and ribavirin in a treatment experienced, hepatitis C virus null-responder patient population.

1 Apr 2011

Treatment for HBV infection with entecavir followed by lamivudine results in virologic rebound

A two-year trial of entecavir followed by lamivudine (LAM) in patients with chronic hepatitis B virus (HBV) infection resulted in a virologic rebound rate of 24% and 12% drug-resistance rate. Patients who continued on entecavir therapy throughout the study period had undetectable HBV DNA at the two-year endpoint. Details of this trial are published in the April issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases.

1 Apr 2011

Vertex announces interim results from VX-222 ongoing Phase 2 study against hepatitis C

Vertex Pharmaceuticals Incorporated today announced interim results from an ongoing Phase 2 study designed to assess the safety and tolerability of 12-week response-guided treatment regimens with its polymerase inhibitor, VX-222, and its protease inhibitor, telaprevir, in combination with pegylated-interferon and ribavirin in people with genotype 1 chronic hepatitis C who were new to treatment.

31 Mar 2011

Positive top-line data from Inhibitex INX-189 Phase 1b trial against HCV

Inhibitex, Inc. today reported positive top-line safety and antiviral data from its multiple ascending dose Phase 1b clinical trial of INX-189, an oral nucleotide polymerase inhibitor being developed to treat chronic infections caused by hepatitis C virus.

31 Mar 2011

South Sudan faces serious health challenges as new nation, Lancet Newsdesk reports

In South Sudan, which is poised to become "the world's newest country" in July, "90% of the population lives on less than $1 a day," and the region is plagued by multiple systemic health issues as a result of years of war, Lancet Infectious Diseases Newsdesk reports.

31 Mar 2011

NEJM publishes MSD's VICTRELIS two pivotal Phase III studies against HCV

MSD, known as Merck in the United States and Canada, announced today that final results from the two pivotal Phase III studies of VICTRELIS, its investigational oral hepatitis C protease inhibitor, will be published in the March 31st edition of The New England Journal of Medicine.

31 Mar 2011

Disease/Infection News

Scientists engineer new protein that prevents HIV virus entry into cells

EPIDEMICS³ International Conference on Infectious Disease Dynamics to take place in Boston, in Nov 2011

New research finds HIV virus's V3 loop as attractive vaccine target

U.N. Secretary-General releases report assessing global response to HIV/AIDS

Study: Pseudokinases can play a crucial role in pathogen-based disease

Novartis, Intercell to initiate Pseudomonas vaccine trial in ventilated ICU patients

Tibotec presents TMC435 phase 2b study interim results against HCV at EASL meeting

New data confirms antiviral activity of fluvastatin in patients with HCV

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

DNA damage can lead to regulation of inflammatory responses

Study: Electronic faucets more likely to become contaminated with bacteria

Vertex announces final results from Phase 3 REALIZE study against HCV

Biota Scientific receives BARDA contract to develop single-dose antiviral drug

Hands-free electronic water faucets more likely to be contaminated with hazardous bacteria

Conatus CTS-1027 Phase 2 trial results against HCV presented at EASL meeting

Treatment for HBV infection with entecavir followed by lamivudine results in virologic rebound

Vertex announces interim results from VX-222 ongoing Phase 2 study against hepatitis C

Positive top-line data from Inhibitex INX-189 Phase 1b trial against HCV

South Sudan faces serious health challenges as new nation, Lancet Newsdesk reports

NEJM publishes MSD's VICTRELIS two pivotal Phase III studies against HCV

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest News